title: Design of therapeutic vaccines as a novel antibody therapy for cardiovascular diseases.
abstract: Vaccines are primarily used worldwide as a preventive medicine for infectious diseases and have recently been applied to cancer. We and others have developed therapeutic vaccines designed for cardiovascular diseases that are notably different from previous vaccines. In the case of cancer vaccines, a specific protein in cancer cells is a target antigen, and the activation of cytotoxic T cells (CTL) is required to kill and remove the antigen-presenting cancer cells. Our therapeutic vaccines work against hypertension by targeting angiotensin II (Ang II) as the antigen, which is an endogenous hormone. Therapeutic vaccines must avoid CTL activation and induce the blocking antibodies for Ang II. The goal of our therapeutic vaccine for cardiovascular diseases is to induce the specific antibody response toward the target protein without inducing T-cell or antibody-mediated inflammation through the careful selection of the target antigen, carrier protein and adjuvants. The goal of our therapeutic vaccine is similar to that of antibody therapy. Recently, multiple antibody-based drugs have been developed for cancer, immune-related diseases, and dyslipidemia, which are efficient but expensive. If the effect of a therapeutic vaccine is nearly equivalent to antibody therapy as an alternative approach, the lower medical cost and improvement in drug adherence can be advantages of therapeutic vaccines. In this review, we will describe our concept of therapeutic vaccines for cardiovascular diseases and the future directions of therapeutic vaccines as novel antibody therapies.
authors.affiliation: Department of Health Development and Medicine, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan. Electronic address: nakagami@cgt.med.osaka-u.ac.jp.
authors.forename: Hironori
authors.initials: H
authors.lastname: Nakagami
mesh_terms: D000804:Angiotensin II / Q000276:immunology; D000818:Animals; D000906:Antibodies / Q000627:therapeutic use*; D001324:Autoantigens / Q000276:immunology; D002318:Cardiovascular Diseases / Q000276:immunology / Q000628:therapy*; D006801:Humans; D014612:Vaccines / Q000627:therapeutic use*
chemical_list: D000906:Antibodies; D001324:Autoantigens; D014612:Vaccines; D000804:Angiotensin II
keywords: Antibody; Self-antigen; Vaccine